Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen Inc.    AMGN

AMGEN INC.

(AMGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
237.57(c) 236.59(c) 237.74(c) 241.66(c) 245.49(c) Last
2 600 537 1 771 566 1 412 300 2 594 082 2 854 071 Volume
-0.39% -0.41% +0.49% +1.65% +1.58% Change
More quotes
Financials (USD)
Sales 2020 25 378 M - -
Net income 2020 7 218 M - -
Net Debt 2020 18 313 M - -
P/E ratio 2020 20,5x
Yield 2020 2,59%
Sales 2021 26 420 M - -
Net income 2021 8 279 M - -
Net Debt 2021 14 398 M - -
P/E ratio 2021 17,5x
Yield 2021 2,76%
Capitalization 143 B 143 B -
EV / Sales 2020 6,35x
EV / Sales 2021 5,95x
Nbr of Employees 23 400
Free-Float 99,8%
More Financials
Company
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN... 
Sector
Pharmaceuticals
Calendar
01/29 | 08:00pmPresentation
More about the company
Notations Surperformance© of Amgen Inc.
Trading Rating : Investor Rating :
More Ratings
All news about AMGEN INC.
01/13AMGEN : Discussing COVID-19, Chronic Disease and the New U.S. Administration on ..
PU
01/13MODERNA : Jose M. Vega, M.D. Joins Moderna as Chief Safety Officer
AQ
01/13AMGEN : in Autoimmune Collaboration With EVOQ Therapeutics
DJ
01/12AMGEN : to Showcase New Data From Its Oncology Pipeline in Lung Cancer at the Wo..
PU
01/12AMGEN : To Showcase Next Frontier Of Innovation In Lung Cancer Therapies At WCLC..
PR
01/11AMGEN : to Invest Over $200 Million in Bid to Reach New Environmental Targets
DJ
01/11AMGEN : Plans $200 Million Investment in Seven-Year Environmental Sustainability..
MT
01/11AMGEN : To Achieve Carbon Neutrality By 2027
PR
01/11Grail in Minimum Residual Disease Collaborations With Amgen, AstraZeneca, Bri..
DJ
01/11Grail Teams Up With Amgen, AstraZeneca, Bristol Myers Squibb to Evaluate Canc..
MT
01/11OPTIONS : Option Implied Volatility Into JPMorgan 39th Healthcare Conference 202..
MT
01/08Stocks Close at Fresh Highs as Biden Promises 'Trillions of Dollars' in Stimu..
MT
01/07AMGEN : Paper Selected for Best of Cell, a Rare Honor for Industry Scientists
PU
01/07MODERNA : Appoints Former Amgen Executive Corinne Le Goff Chief Commercial Offic..
MT
01/06AMGEN : To Present At The 39th Annual J.P. Morgan Healthcare Conference
PR
More news
News in other languages on AMGEN INC.
2020AMGEN INC : RBC n'est pas inspiré par le dossier
2020RBC belässt Amgen auf 'Sector Perform'
2020WALL STREET STOCK EXCHANGE : USA-Les valeurs à suivre à Wall Street
2020Molecular Partners vise une homologation contre le Covid-19 en 2021
2020Les valeurs à suivre aujourd'hui à Wall Street Mardi 10 novembre 2020
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | AMGN | US0311621009 | MarketScreener
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 253,92 $
Last Close Price 245,49 $
Spread / Highest target 23,8%
Spread / Average Target 3,44%
Spread / Lowest Target -24,6%
EPS Revisions
Managers and Directors
NameTitle
Robert A. Bradway Chairman, President & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
Peter H. Griffith Chief Financial Officer
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN INC.6.77%142 917
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993